Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Tool for Automatic Colorectal Cancer Tissue Analysis Outperforms Prior Methods

By LabMedica International staff writers
Posted on 26 Oct 2023

Colorectal Cancer (CRC) ranks as the third most prevalent and the second most lethal cancer. More...

Catching it early and treating it promptly are extremely important. While machine vision technologies have seen remarkable improvements in automatically classifying types of cancer, they largely rely on deep neural networks with millions of parameters fine-tuned for diagnostic and prognostic tasks. Even though deep learning has shown extraordinary capabilities, healthcare professionals still have to inspect biopsied tissue samples to verify the diagnosis and assess the stage of the tumor. To advance this field further, scientists have now introduced an artificial intelligence (AI) solution specifically designed for automated analysis of colorectal cancer tissue that outperforms previous techniques.

The refined neural network developed by researchers from the University of Jyväskylä (Jyväskylä, Finland) has set new performance benchmarks in colorectal cancer tissue analysis. The AI-based system offers a more accurate and quicker way to categorize tissue samples of colorectal cancer from microscope slides. This advancement could significantly ease the work burden on histopathologists, thus enabling faster and more precise prognoses and diagnoses. Despite the promising results, it is important to be cautious while incorporating AI into medical practice.

As AI technologies move closer to becoming a standard part of clinical procedures, it becomes increasingly vital that they go through rigorous clinical validation. This is to ensure that the results they produce are consistently in line with established clinical norms. In a move encouraging collaborative development, the researchers are making this trained neural network publicly available. Their aim is to accelerate progress in the field by allowing scientists, researchers, and developers from around the world to further refine the tool and explore its various potential applications.

“By granting universal access, the aim is to fast-track breakthroughs in colorectal cancer research,” said Fabi Prezja, who was responsible for the design of the method.

Related Links:
University of Jyväskylä 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Specimen Radiography System
TrueView 200 Pro
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.